Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Return on Invested Capital (2022 - 2025)

Prime Medicine's Return on Invested Capital history spans 4 years, with the latest figure at 1.59% for Q1 2025.

  • For Q1 2025, Return on Invested Capital fell 46.0% year-over-year to 1.59%; the TTM value through Mar 2025 reached 1.59%, down 46.0%, while the annual FY2023 figure was 0.91%, 54.0% up from the prior year.
  • Return on Invested Capital reached 1.59% in Q1 2025 per PRME's latest filing, down from 1.01% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.66% in Q3 2022 to a low of 2.48% in Q4 2022.
  • Average Return on Invested Capital over 4 years is 0.8%, with a median of 0.91% recorded in 2024.
  • The largest YoY upside for Return on Invested Capital was 123bps in 2023 against a maximum downside of -147bps in 2023.
  • A 4-year view of Return on Invested Capital shows it stood at 2.48% in 2022, then surged by 50bps to 1.25% in 2023, then increased by 19bps to 1.01% in 2024, then crashed by -56bps to 1.59% in 2025.
  • Per Business Quant, the three most recent readings for PRME's Return on Invested Capital are 1.59% (Q1 2025), 1.01% (Q2 2024), and 1.13% (Q1 2024).